Becaplermin

Source: Wikipedia, the free encyclopedia.
Becaplermin
Clinical data
Topical
ATC code
Legal status
Legal status
Identifiers
CAS Number
DrugBank
ChemSpider
  • none
UNII
ChEMBL
CompTox Dashboard (EPA)
 ☒NcheckY (what is this?)  (verify)

Becaplermin (brand name Regranex) is a

cicatrizant, available as a topical gel. Regranex is a human platelet-derived growth factor indicated along with good wound care for the treatment of lower extremity diabetic neuropathic ulcers.[1] It is also known as "platelet-derived growth factor BB".[1]

Medical uses

The drug is used for the treatment of

foot ulcers.[2] Studies of becaplermin showed that when used with good wound care, complete healing significantly increased and the ulcers healed on average 6 weeks faster.[3] Pharmacoeconomic studies reinforce the cost effectiveness of becaplermin as an adjunct to good wound care.[4]

The amount of becaplermin to be applied will vary depending upon the size of the ulcer area. Becaplermin should be stored in the refrigerator.[1] Analysis of healing human wounds showed that PDGF-BB induces fibroblast proliferation and differentiation and was found to increase healing in patients with decreased healing capacity, such as people living with diabetes. [5]

Contraindications

Becaplermin must not be used at the site of a skin cancer.[6]

Adverse effects

The most common side effects in clinical studies were

erythematous rashes.[6]

A boxed warning has been added to the safety label to describe an increase rate of death from cancer when three or more tubes are used.[7] Regranex should be used with caution in patients with known malignancy.[1]

References

  1. ^ a b c d "REGRANEX Gel Highlights of Prescribing Information" (PDF). Smith & Nephew, Inc. Archived from the original (PDF) on 26 August 2016.
  2. S2CID 28408255
    .
  3. .
  4. .
  5. ^ Heldin CH, Westermark B. Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev. 1999;79:1283-1316.
  6. ^ a b FDA Professional Drug Information for Regranex.
  7. ^ Waknine Y (9 June 2008). "Diabetic Ulcer Gel Gets Black Box Warning". Medscape.